Personalized transplant approach targets genetic blood cancers
NCT ID NCT07524530
First seen Apr 18, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tests whether adjusting chemotherapy and supportive care doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by RUNX1 gene mutations. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goal is to see if this tailored approach increases the number of patients who are alive and cancer-free one year later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stem cell transplant with chemotherapy (cyclophosphamide, busulfan, fludarabine)
What this could lead to
If successful, this could show that personalized chemotherapy doses improve survival after stem cell transplant for people with RUNX1-related blood cancers.
What could go wrong
This is a Phase II trial with only 98 participants, so results may not apply to everyone. Stem cell transplants carry risks like infection, graft-versus-host disease, and organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.